Efficacy and Safety of Three Insulin Protocols in Medical Intensive Care Unit Patients

Sponsor
Hospital Israelita Albert Einstein (Other)
Overall Status
Completed
CT.gov ID
NCT00410852
Collaborator
Fundação de Amparo à Pesquisa do Estado de São Paulo (Other)
168
5
3
22
33.6
1.5

Study Details

Study Description

Brief Summary

To evaluate the efficacy and safety of three insulin algorithms in medical ICU patients (MICU).

Condition or Disease Intervention/Treatment Phase
  • Procedure: Computer-assisted IV insulin infusion protocol (algorithm A)
  • Procedure: Leuven Strict glycemic control protocol (Algorithm B)
  • Procedure: Conventional Intermittent Insulin Protocol (Algorithm C)
N/A

Detailed Description

Strict glycemic control has been recommended for critically ill patients. However, its implementation may face difficulties with increased nursing workload, inadequate glucose control and higher risk of hypoglycemia.

We designed a computer guided protocol to adjust endovenous insulin infusion aiming glucose levels between 100mg/dl and 130 mg/dl. This trial evaluates the efficacy and safety of this protocol (algorithm A), compared to a standard endovenous insulin infusion protocol (algorithm B) and a conventional subcutaneous insulin protocol (algorithm C).

Methods : MICU patients with at least one blood glucose ≥ 150 mg/dL and who are on mechanical ventilation, or had SIRS, or are admitted because of trauma or burn will be randomized to one of the following treatments: algorithm A - continuous insulin infusion with adjustments guided by hand held device or desktop software targeting glucose levels between 100mg/dL-130mg/dL; algorithm B - continuous insulin aiming glucose levels between 80mg/dl-110mg/dl using Van den Berghe's insulin protocol; algorithm C - conventional treatment - intermittent subcutaneous administration of insulin if blood glucose levels exceeds 150mg/dL; insulin will be administered as IV boluses in hypotensive patients.

The randomization list was generated in blocks of six by computer software. Patients will be randomly assigned in a 1:1:1 ratio to have their glucose controlled by one of the three insulin algorithms with the use of a central, computerized system accessed by Internet, permitting concealment of allocation list. Randomization will be stratified according to study site.

The study is planned to enroll 165 patients in order to have 80% power to detect a 20mg/dl difference in blood glucose means between groups, assuming standard deviation equal to 33 mg/dl and two-tailed alpha equal to 0.05. Efficacy will be measured by the mean of patients' median blood glucose and safety measured by the incidence of hypoglycemia (≤40 mg/dL). Analysis will follow the intention-to-treat principle.

Study Design

Study Type:
Interventional
Actual Enrollment :
168 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Randomized Study to Evaluate the Efficacy and Safety of Two Endovenous Insulin Protocols and a Subcutaneous Insulin Protocol in Critically Ill Patients
Study Start Date :
May 1, 2005
Actual Study Completion Date :
Mar 1, 2007

Arms and Interventions

Arm Intervention/Treatment
Experimental: A

Procedure: Computer-assisted IV insulin infusion protocol (algorithm A)
Computer assisted insulin protocol (CAIP), with continuous intravenous insulin adjustments aiming blood glucose levels between 100 mg/dl and 130 mg/dl.

Experimental: B

Procedure: Leuven Strict glycemic control protocol (Algorithm B)
Leuven protocol: continuous intravenous insulin infusion aimiming blood glucose levels between 80mg/dl and 110mg/dl.

Active Comparator: C

Procedure: Conventional Intermittent Insulin Protocol (Algorithm C)
Conventional treatment: intermitent subcutaneous insulin according to a sliding scale, starting with blood glucose levels higher than 150mg/dl.

Outcome Measures

Primary Outcome Measures

  1. Efficacy: mean of patients' median blood glucose during ICU stay [ICU Stay]

  2. Safety: incidence of hypoglycemia (≤40 mg/dL)during ICU stay [ICU stay]

Secondary Outcome Measures

  1. Death from any cause [ICU and in-hospital]

  2. ICU and hospital length of stay [ICU and in-hospital]

  3. Five-day variation in SOFA score [Five days]

  4. 90-day health status [90 days]

  5. Days on mechanical ventilation []

  6. Initiation of dialysis []

  7. Days on antibiotics []

  8. Days on inotropic of vasopressor support []

  9. Necessity of red blood cell transfusions []

  10. Bilirubin peak []

  11. Platelets through []

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Criteria 1, 2 and 3 must be present:
  1. Clinical patients admitted to an Intensive Care Unit

  2. At least one blood glucose measurement >= 150 mg/dL (capilar, venous or arterial blood)

  3. At least one of the following:

  4. Patient on mechanical ventilation for an acute process, with expected duration of mechanical ventilation of at least 24 hours

  5. Polytrauma patients

  6. Severe burn patients

  7. Systemic Inflammatory Response Syndrome (modified criteria), with at least three of the following: core temperature >=38°C or <=36°C; heart rate >=90 beats/min, except in patients with a medical condition or receiving a medication known to prevent tachycardia; respiratory heart rate >= 20 breaths/min or a PaCO2 <=32mmHg, or the use of mechanical ventilation for an acute process; white-cell count of >=12.000/mm3 or <=4.000/mm3 or a differential count showing >10% percent immature neutrophils

Exclusion Criteria:
  • Age < 21 years

  • Surgical patients (surgery less than 24hs before admission to ICU)

  • Diabetic ketoacidosis

  • Non-ketotic hyperosmolar state

  • Patients with defined diagnosis of brain death

  • Moribund state in which death is perceived to be imminent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Complexo Hospitalar UNIMED Joinville Santa Catarina Brazil
2 Hospital Dona Helena Joinville Santa Catarina Brazil
3 Hospital Regional Sao Jose Joinville Santa Catarina Brazil
4 Hospital Estadual Mario Covas Santo Andre Sao Paulo Brazil
5 Hospital Israelita Albert Einstein Sao Paulo Brazil 05651-901

Sponsors and Collaborators

  • Hospital Israelita Albert Einstein
  • Fundação de Amparo à Pesquisa do Estado de São Paulo

Investigators

  • Study Chair: Alexandre B Cavalcanti, MD, Hospital Israelita Albert Einstein
  • Study Director: Eliezer Silva, PhD, Hospital Israelita Albert Einstein
  • Study Director: Jose Eluf-Neto, PhD, Departamento de Medicina Preventiva, Faculdade de Medicina da Universidade de Sao Paulo
  • Principal Investigator: Milton Caldeira, MD, Hospital Regional Sao Jose
  • Principal Investigator: Glauco Westphal, MD, Centro Hospitalar UNIMED

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00410852
Other Study ID Numbers:
  • FAPESP 2005/50557-5
First Posted:
Dec 13, 2006
Last Update Posted:
Nov 2, 2007
Last Verified:
Oct 1, 2007
Keywords provided by , ,
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 2, 2007